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ParainfluenzaAbstract Background: Community acquired viruses (CRVs) may cause severe disease in can-
cer patients. Thus, efforts should be made to diagnose CRV rapidly and manage CRV infec-
tions accordingly.
Methods: A panel of 18 clinicians from the Infectious Diseases Working Party of the German
Society for Haematology and Medical Oncology have convened to assess the available litera-
ture and provide recommendations on the management of CRV infections including influenza,
respiratory syncytial virus, parainfluenza virus, human metapneumovirus and adenovirus.
Results: CRV infections in cancer patients may lead to pneumonia in approximately 30% of
the cases, with an associated mortality of around 25%. For diagnosis of a CRV infection, com-
bined nasal/throat swabs or washes/aspirates give the best results and nucleic acid amplifica-
tion based-techniques (NAT) should be used to detect the pathogen. Hand hygiene, contact
isolation and face masks have been shown to be of benefit as general infection management.
Causal treatment can be given for influenza, using a neuraminidase inhibitor, and respiratory
syncytial virus, using ribavirin in addition to intravenous immunoglobulins. Ribavirin has also
been used to treat parainfluenza virus and human metapneumovirus, but data are inconclusive
in this setting. Cidofovir is used to treat adenovirus pneumonitis.
Conclusions: CRV infections may pose a vital threat to patients with underlying malignancy.
This guideline provides information on diagnosis and treatment to improve the outcome.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The importance of community acquired respiratory
virus (CRV) infections is increasingly recognised. CRV
are responsible for respiratory infections, which usually
present as a common cold in the immunocompetent
individual but may be life-threatening in the immuno-
compromised host. Usually, orthomyxoviridae (influ-
enza A, B and C), paramyxoviridae (including
parainfluenza 1e4 [PIV], respiratory syncytial virus A
and B [RSV], and human metapneumovirus [hMPV]),
coronaviridae, picornaviridae (including >100 different
serotypes of rhinovirus and enterovirus), adenoviridae,
polyomavirus type 1 and bocavirus are regarded as
potential causes of CRV infection. This guideline is
intended to give haematologists and oncologists a broad
overview with regard to clinical relevance and diagnosis
of CRV infection and management of cancer patients
affected by CRV. Detailed information on respective
viruses including emerging resistance is not the scope of
this guideline. Most data on this topic originate from
patients following allogeneic stem cell transplantation
(allo-SCT), and we know little about CRV infections incancer patients outside the setting of allo-SCT. How-
ever, in recent years increasing evidence has been gath-
ered about other cancer patients, revealing clinical
relevance of CRV infections in non-transplant patients.
Therefore, this guideline discusses CRV infections in all
cancer patients with ongoing relevant immunosuppres-
sion. It is left to the treating physician to assess the
degree and relevance of immunosuppression in the in-
dividual patient.
2. Methods
This guideline has been developed by a panel from the
Infectious Diseases Working Party (AGIHO) of the
German Society of Haematology and Medical
Oncology including 17 experts certified in internal
medicine, haematology/oncology, infectious diseases,
microbiology/virology or radiology and one medical
student. First, predefined topics were delivered by the
designated coordinator (MvLT) to all participants of the
panel to form subgroups. Data were extracted and
tabulated after a systematic literature search by sub-
group members and revised in several steps by the
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discussion process and a face-to-face meeting. Finally,
preliminary recommendations of the panel were dis-
cussed, revised and approved by the AGIHO assembly.
In May 2014, the first literature search was performed
for CRV and immunosuppression using the terms
‘-virus’ and ‘immunocompromised’ (for example:
‘adenovirus immunocompromised’). This search was
performed for adenovirus, bocavirus, coronavirus,
enterovirus, hMPV, influenza, PIV, parechovirus, RSV
and rhinovirus. The references were then screened by the
subgroup members and relevant articles retrieved as full
papers. Wherever applicable, additional papers were
identified in the reference lists and treated as described.
In February 2016, an update of the literature search was
performed.
For grading, the system applied by the European
Society of Clinical Microbiology and Infectious Dis-
eases as proposed by Ullmann et al., in 2012 [1] was
used (Table 1) with one modification: other than Ull-
mann et al., we used the same grading of the strength ofTable 1
Grading of evidence as suggested by the ESCMID [1].
Strength of recommendation
A Strongly support a recommendation for use
B Moderately support a recommendation for use
C Marginally support a recommendation for use
D Support a recommendation against use
Quality of evidence for interventionsdlevel
I Evidence from at least one properly designed randomized,
controlled trial
II* Evidence from at least one well-designed clinical trial, without
randomization; from cohort- or case-control analytic studies
(preferably from more than one centre); from multiple time
series; or from dramatic results from uncontrolled experiments.
III Evidence from opinion of respected authorities, based on
clinical experience, descriptive case studies, or report of expert
committees
*Added index
R Meta-analysis or systematic review of randomized controlled
trials
T Transferred evidence, i.e. results from different patients’
cohorts or similar immune status situation
H Comparator group is a historical control
U Uncontrolled trial
A Abstract published at an international meeting
Quality of evidence for diagnostic measuresdlevel
I Evidence from at least one properly designed multicentre cross-
sectional or cohort study
II Evidence from
(1) At least one well-designed prospective singlecentre
cross-sectional or cohort study or
(2) A properly designed retrospective multicentre cross-
sectional or cohort study or
(3) From case-control studies
III Evidence from opinion of respected authorities, based on
clinical experience, descriptive case studies, or report of expert
committeesrecommendation for diagnostic measures as for in-
terventions (Table 1). The results of the literature
search and the following grading process were used to
develop recommendations wherever possible. Recom-
mendations and evidence were then presented at and
approved by the AGIHO assembly during the spring
meeting on 6th March 2015. Following the update of
the literature search in February 2016 no relevant
changes were made.3. Diseases caused by CRV
CRVs cause respiratory tract infections, which can be
divided into upper respiratory tract infection (URTI),
influenza-like illness (ILI) and lower respiratory tract
infection/pneumonia (LRTI). Commonly, URTI can be
assumed, if a patient has a new onset of symptoms
including at least one of cough, coryza, sore throat or
shortness of breath which is deemed to be due to an
infection by the treating physician. LRTI requires clin-
ical or radiological evidence of pneumonia [2]. ILI is
diagnosed in patients with a sudden onset of new
symptoms including at least one of fever or feverishness,
malaise, headache or myalgia and at least one of the
respiratory symptoms cough, sore throat or shortness of
breath [3]. To be certain of the viral origin, the detection
of the virus from respiratory samples like swabs, naso-
pharyngeal aspirates or bronchoalveolar lavage fluid is
required. Of note, surveillance studies showed some
patients to be asymptomatic but still shedding the virus
[2,4e7]. For that reason, some authors distinguish be-
tween respiratory infection (detection of virus indepen-
dent of symptoms) and respiratory infection disease
(detection of virus and respective symptoms) [8]. How-
ever, for the purpose of this guideline, we omit this
distinction and define URTI, LRTI and ILI as described
above.4. Epidemiology and clinical relevance
Some CRV like influenza or RSV have a seasonality
with most infections occurring during the winter months
[2,9,10]. Others like rhinovirus or parainfluenza are in-
dependent of seasonality [11]. Thus, an appropriate
diagnostic work-up and clinical management is war-
ranted in any patient presenting with typical symptoms
regardless of the time of the year. As may be expected
considering the nature of the disease, CRV frequently
cause outbreaks in health care settings [7,12e15].
Importantly, outbreaks may also occur in outpatient
settings [16] emphasising the need for awareness during
all periods of cancer treatment.
Generally, viral URTI in cancer patients has some
impact on the clinical course because the patients are
symptomatic to a degree that frequently requires post-
ponement of chemotherapy [17]. However, critical
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contrast, most patients who died were suffering from
LRTI, which thus poses the biggest threat to cancer
patients. Rates of LRTI and mortality differ amongst
the respective CRV [18] and exact estimation is
hampered by the fact that fatal cases are probably over-
reported. We have tried to deduce reliable information
on LRTI and mortality from the literature for various
CRV: influenza appears to have a high rate of LRTI
with approximately 30% and an associated mortality
rate of approximately 25% [19e22]. RSV appears to be
at least as dangerous with a rate of LRTI of approxi-
mately 33% and an associated mortality rate of 27% [16].
However, it has to be kept in mind, that most data
regarding RSV originate from SCT-recipients and very
little is known regarding patients with other forms of
malignancy. On the other hand, there are several reports
of outbreaks in general haematology/oncology units,
which showed a significant disease burden even in pa-
tients not undergoing stem cell transplantation [12].
With regard to hMPV and PIV, exact information on
the clinical relevance is even more difficult to obtain.
However, although both viruses may cause asymptom-
atic infection [6,23], the available evidence suggests a
similar overall rate of LRTI and mortality
[7,11,13,24e28] compared with influenza and RSV. In
contrast, despite case reports of fatal outcomes of in-
fections with rhinovirus and coronavirus, these viruses
as well as bocavirus appear to be rarely the cause of
LRTI and dangerous only when patients are coinfected
with other pathogens [2,5,29]. Herpesviridae like herpes
simplex virus, human herpes virus 6, cytomegalovirus,
varicella zoster and EpsteineBarr virus as well as pol-
yomaviruses or parechoviruses usually do not cause
CRV infection. Pneumonia due to reactivation of her-
pesviridae in severely immunocompromised patients is
not an infection by CRV and thus not covered by this
guideline.
In CRV infection, coinfection with bacteria, fungi or
even other viruses appears to occur in approximately
30% of the patients [10,11,28]. They play a vital role with
regard to outcome of patients since patients with bac-
terial or fungal superinfection have a dramatically
higher mortality rate than those with viral infection only
[11,28]. Therefore, possible co- or superinfection should
be considered when managing cancer patients with
CRV. In addition to LRTI and bacterial or fungal su-
perinfection, other risk factors for adverse outcome
include haematological malignancy [22], severe immu-
nosuppression such as steroid use or graft versus host
disease or cytopenias [30e32] or low immunoglobulins
[12].
Epidemiology of adenoviruses is somewhat different
from the other CRV: often, the source of infection is a
childhood infection in children under 5 years [33] and
reactivation as well as new infection have been described
to be the cause of disease [34,35]. Other than CRVs likeRSV or influenza, adenoviruses can cause a variety of
symptoms such as conjunctivitis, haemorrhagic cystitis,
gastroenteritis, and URTI in immunocompetent pa-
tients and hepatitis, colitis, nephritis, meningoencepha-
litis and LRTI in the immunocompromised host. In
adult allo-SCT recipients, DNAemia occurs in up to
20% [36e38], but symptomatic disease by adenovirus is
much less common with T-cell suppression being the
predominant risk factor [36]. Again, coinfection is an
important risk factor for severe illness [39].5. Diagnosis of CRV infection
5.1. Virologydmaterial
Cancer patients presenting with symptoms consistent
with CRV infection should be diagnosed using material
from the respiratory tract (Table 2). Serology is not
useful to detect ongoing CRV infection and thus not
recommended (D III). Regarding material used for
microbiological diagnosis, a variety of approaches are
used in various centres. As a general rule, a close
collaboration with the local microbiology laboratory is
highly recommended because this may determine which
material should be used preferably since commercially
available test kits are licensed for specific materials. For
example testing for viral antigens usually requires more
thorough sampling like combined nasal/throat swabs
than testing for viral nucleic acids which can often be
performed reliably on gargles alone. It is therefore
essential for the clinician to be aware of the tests used in
the respective laboratory. The overall evidence in the
literature is best for combined nasal/throat swabs and
nasopharyngeal aspirates (A IIt, Table 2).
5.2. Virologydtest
The best evidence for reliable detection of a CRV pre-
sent in respiratory samples exists for nucleic acid
amplification based-techniques (NAT) like PCR.
Therefore, the use of NAT is highly recommended (A II,
Table 2) and any methods involving the detection of
antigen appear to be second best in immunosuppressed
cancer patients (C II [40e42]). Also, culture methods are
not commonly used anymore and cannot be recom-
mended for general diagnosis, but they are essential in
individual cases in which no known virus can be detec-
ted or results of PCR-analysis are inconclusive (A II,
[43]). In the era of multiplex-test kits, it is difficult to
make a definite recommendation with regard to which
viruses should be looked for. In the absence of any
reliable data regarding this question, the panel feels that
it is wise to search for influenza, RSV, PIV and viruses
currently prevalent in the local environment in all
immunosuppressed cancer patients presenting with
symptoms. Patients with more severe disease (for
Table 2
Recommendations regarding diagnostic approaches in cancer patients with symptoms of CRV infection.
Population Intention Intervention SoR QoE Reference
Symptomatic IS To detect viral pathogen
and diagnose infection
Serology D III [94]
Symptomatic IS To detect viral pathogen Combined nasal/throat
swabs or washes/aspirates
A II [95e103]
Symptomatic IS To detect viral pathogen NAT A II [42,94,104e107],
Symptomatic IS To detect LRTI in patients
with CRV infection
Chest X-ray D II [108]
Symptomatic IS To detect LRTI in patients
with CRV infection
CT scan A II [44,46,47,69,108e115],
SoR, strength of recommendation; QoE, quality of evidence; IS, immunosuppressed cancer patients; NAT, nucleic acid amplification techniques;
LRTI, lower respiratory tract infection; CRV, community acquired respiratory virus; CT, computer tomography.
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panel broadened to include hMPV and adenovirus and
even viruses that only rarely cause LRTI like rhinovirus
and coronavirus. However, evidence for this approach is
low and it is strongly advisable to define local guidelines
on this topic. It should be kept in mind, that herpes-
viridae are not the cause of CRV infection. Therefore,
there is no rationale to look for cytomegalovirus, Eps-
teineBarr virus, herpes simplex virus or varicella zoster
in patients with typical symptoms of CRV infection
only.
5.3. Radiology
In patients with symptoms of LRTI, it is essential to
determine the degree of pulmonary involvement. CRV
can affect the tracheobronchial system or the lung pa-
renchyma [44]. Generally, a chest X-ray has been proven
to be unhelpful to diagnose pathologic changes in this
setting because of lack of sensitivity. It is therefore not
recommended (D II, see Table 2). In contrast, there is
good evidence to recommend a CT scan of the chest to
detect LRTI in patients with CRV infection (A II, see
Table 2). Bronchial wall thickening as well as interstitial
infiltrates presenting as ground-glass opacities may be
detected. These are defined as increased lung density,
whereas underlying lung architecture is still detectable.
Ground-glass opacities may be patchy or diffuse [44e47]
and can be well distinguished from consolidations,
which show higher density obscuring e.g. the pulmonary
vessels and which are typical for other differential di-
agnoses including bacterial infection. Affection of the
terminal bronchioles might lead to visibility of those
usually invisible structures at CT as small centrilobular
nodules or ‘tree-in-bud’ sign [45] or evidence of bron-
chiolitis causing air-trapping. To reliably detect air-
trapping while inspiratory CT is normal, a CT scan in
expiration is necessary [44]. In addition to good diag-
nostic accuracy with regard to the diagnosis of a viral
LRTI, the CT scan may also reveal evidence for an
outbreak, since specific viruses tend to present with a
typical pattern in the CT scan [45]. For an example see
Fig. 1.6. Management of CRV infection
6.1. Infection control
In the light of the danger of outbreaks with fatal con-
sequences, the most important measure in the manage-
ment of cancer patients with CRV infection is infection
control (Table 3). Local authorities should give exact
guidance on the necessary precautions in the respective
institutions. The following statements intend to give a
general overview.
There is sufficient evidence to recommend stringent
hand hygiene (A IIt), the use of face masks (B IIt) and
contact isolation (A III, Table 3). Importantly, shedding
of CRV in cancer patients often lasts 2 weeks or longer
[5,10,48]. It is therefore wise to perform follow-up
testing of respiratory material in index patients and
stop contact isolation only when they became negative.
Of note, early implementation of infection control ap-
pears to be more effective than late implementation [49]
which gives reason to recommend infection control as
soon as symptoms appear and not only after evidence of
CRV.
6.2. Supportive measures
Almost anybody who catches a cold applies some form
of home remedies convinced that they ease the symp-
toms and positively influence the course of the disease.
In contrast to this widespread use, there is very little
evidence to recommend any such measures. In particular
with regard to cancer patients, evidence is too poor to
give a sound recommendation in favour of the use of
vitamin C [50], echinacea [51], garlic [52], zinc [53], hu-
midified hot air [54] or Chinese herbal medicine [55].
Surprisingly, even painkillers [56] and non-steroidal
anti-inflammatory drugs [57] may ease the pain but
have little influence on severity and duration of the CRV
infection. However, as there is some evidence towards a
considerable placebo effect [58], it can be argued that
patients should be allowed to continue their home
remedies provided there is no reason to assume harm-
fulness as may be the case for some Chinese herbal
Fig. 1. AeB: pneumonia caused by influenza, first CT scan (A) and follow-up scan after 4 d (B). The bilateral diffuse ground-glass
opacities progress over time to cover most parts of the lung. In addition, consolidations with positive bronchopneumogram develop,
indicative of possible bacterial superinfection. CeE: CT scans from three different patients with pneumonia caused by RSV. Again,
ground-glass opacities can be found but are of a more patchy character (Fig. 1C). They are often combined with centrilobular nodules
(tree-in-bud, Fig. 1D). In some cases, only nodules with a ground-glass character are detected (Fig. 1E). RSV, respiratory syncytial virus.
Table 3
Recommendations regarding general management of cancer patients with CRV.
Population Intention Intervention SoR QoE Reference
IS, infected persons,
Contact persons
Infection controldprevent transmission Hand hygiene A IIt [49,116]
IS, Infected persons,
Contact persons
Infection controldprevent transmission Face mask B IIt [49,116]
Infected persons Infection controldprevent outbreak Contact isolation A III [117]
allo-SCT and evidence of CRV Prevent disease, improve survival Delay conditioning A II [17]
All other chemotherapy and CRV Prevent disease, improve survival Delay chemotherapy if possible C III [61]
allo-SCT and LRTI due to
adenovirus
Prevent disease, shorten duration Reduce immunosuppression A II [36,62]
allo-SCT and LRTI due to CRV Prevent disease, shorten duration Reduce immunosuppression A IIt [36,62]
allo-SCT and URTI Prevent disease, shorten duration Reduce immunosuppression C III
IS with evidence of CRV Reduce morbidity Steroids >2 mg/kg D III [10]
IS with evidence of RSV Prevent LRTI, improve survival IVIG B III [30,82]
IS with evidence of influenza,
PIV, hMPV
prevent LRTI, improve survival IVIG C III [69,92,118,119]
SoR, strength of recommendation; QoE, quality of evidence; IS, immunosuppressed cancer patients; URTI, upper respiratory tract infection;
LRTI, lower respiratory tract infection; CRV, community acquired respiratory virus; IVIG intravenous immunoglobulins; allo-SCT, allogeneic
stem cell transplantation; RSV, respiratory syncytial virus; PIV, parainfluenza virus; hMPV, human metapneumovirus.
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possibility to contract invasive fungal infection from
inhaling contaminated air.
Needless to say, there is little to be gained from
treating a viral infection with antibiotics [60], which is
also true for cancer patients (D IIr,t for treating viral
infections with antibiotics). However, having in mind
the high rate of superinfection, cancer patients with viral
LRTI and suspected or proven bacterial/fungal coin-
fection have to be treated accordingly (A III).
In cancer patients who present with symptoms
consistent with CRV infection prior to initiation ofchemotherapy, delaying treatment should be consid-
ered. Since a retrospective study with 2 groups showed a
benefit, if treatment was delayed in patients undergoing
allo-SCT, we clearly recommend delaying conditioning
in those patients who are scheduled for allo-SCT and
have evidence of CRV infection (A II, see Table 3). The
situation is less clear for patients with less aggressive
treatment, since there have been reports of uneventful
courses of even high-dose chemotherapy in patients
with initial CRV infection [61]. Therefore, the recom-
mendation to delay the chemotherapy if possible to be
on the safe side is merely a weak one (Table 3).
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LRTI due to adenovirus-infection after allo-SCT is well
founded [36,62] on retrospective cohort studies with 2
groups and is thus clearly recommended (A II, Table 3).
Data can be transferred to the situation of other LRTI
caused by CRV, therefore, reduction of immunosup-
pression is also recommended in allo-SCT recipients
with LRTI caused by other CRV (A IIt, Table 3). In
contrast, the situation is less clear in patients with
URTI and therefore only a very weak recommendation
can be made (C III, Table 3).
With regard to supportive application of systemic
medication other than antivirals, no recommendation
can be made for the use of steroids, since they show no
effect and prolong viral shedding (D III, Table 3). In
contrast, intravenous immunoglobulins (IVIGs) are a
therapeutic option in RSV infection (B III) and may also
be beneficial in influenza, PIV and hMPV infection (C
III, Table 3). Because of lack of data, no recommen-
dation can be made regarding the use of IVIG in other
CRV infections.
7. Causal treatment
7.1. Influenza
If causal treatment was deemed necessary, influenza A
was traditionally treated with amantadine or rimanta-
dine. Nowadays, resistance rates are so high that neither
can be recommended (D II [63e66]). In contrast, despite
ongoing discussion regarding the balance of efficacy and
side effects [67,68] the treatment of choice appears to be
a neuraminidase inhibitor, be it oseltamivir, zanamivir
or peramivir. They are recommended as prophylaxis as
well as for treatment (for example http://www.rki.de/
DE/Content/InfAZ/I/Influenza/IPV/IPV_Node.html or
[63,69,70]). However, data regarding the efficacy of
prophylactic use of neuraminidase inhibitors in cancer
patients are very weak and almost exclusively in the
setting of stem cell transplantation [71,72]. Therefore,
the authors believe it is not justified to give any
recommendation in favour of or against their use in
cancer patients in general. Thus, prevention of influenza
by application of neuraminidase inhibitors remains one
of the unresolved issues requiring further study. Still, weTable 4
Recommendations regarding causal treatment of influenza, RSV, parainflu
Population Intention
IS and influenza Shorten duration and prevent LRTI
IS and influenza Shorten duration and prevent LRTI
IS and RSV Prevent LRTI and improve survival
IS and PIV Prevent LRTI and improve survival
Adenovirus-associated
pneumonitis
Cure
SoR, strength of recommendation; QoE, quality of evidence; IS, immunosu
community acquired respiratory virus; RSV, respiratory syncytial virus; PIhave included information on dose and duration in
Table 5.
Treatment of influenza is usually recommended in
symptomatic patients at high risk preferably <48h after
the onset of symptoms [63]. Cancer patients might be
regarded as high-risk patients per se, which is why
neuraminidase inhibitors (usually oseltamivir) are often
routinely given to patients with malignancies and influ-
enza [69,70,73], since mostly retrospective data show a
benefit of (early) antiviral treatment with regard to
development of LRTI or further complications
[10,20,74e76]. Thus, we do recommend the use of
oseltamivir or zanamivir (B II, Tables 4 and 5). There is
evidence to recommend early initiation of treatment, but
that does not necessarily mean later treatment is futile
[77] and therefore many authors recommend treatment
regardless of timepoint [70]. However, we do not think
either dose (150e300 mg/d) nor duration (5e10 d or
longer) are well defined from the available evidence and
need determination by local specialists. The reasons
usually given for higher doses and longer treatment
duration in high-risk patients is the prolonged viral
shedding observed in cancer patients and a thus deduced
susceptibility to develop resistances if not treated effec-
tively [69,70].
Peramivir has received FDA approval during the
2009 pandemic and is recommended for patients with
H1N1 infection unable to take oral medication [78]. It is
not available in Germany but included in this guideline
for the sake of completeness (Table 5). The authors
advise its use in severe cases, when oral intake or inha-
lation is not possible (CIII). Another salvage option
may be the combination of zanamivir or oseltamivir
with ribavirin, since that has shown some efficacy in
older studies [79].
7.2. RSV
RSV is usually treated with intravenous immunoglobu-
lins (IVIG, B III, Table 3) and ribavirin. In Europe, the
monoclonal antibody palivizumab is licensed for pre-
vention of RSV in children only. In addition, the benefit
over polyclonal IVIG is not entirely conclusive [80]. For
these reasons, we do not make a clear recommendation
for or against its use in cancer patients, since we regardenza and adenovirus.
Intervention SoR QoE Reference
Oseltamivir B II [10,74,76,77]
Zanamivir B II [75,76]
Ribavirin B II [12,30,80e82,86,87]
Ribavirin C III [11,24,79,86,88,89]
Cidofovir B II [120e122]
ppressed cancer patients; LRTI, lower respiratory tract infection; CRV,
V parainfluenza virus.
Table 5
Information on specific drugs.
Name Class Indication Dose Application
mode
Duration Comment Reference
Oseltamivir Neuraminidase
inhibitor
Prophylaxis
influenza
75 mg/d Oral As needed in
seasonal
prophylaxis; 10d in
post-exposure
prophylaxis
Caveat: data too
weak to make a
recommendation,
local strategies
needed
[63,69,71]
Oseltamivir Neuraminidase
inhibitor
Treatment
influenza
2  75-
150 mg/d
Oral 5e10 d [10,74,76,77]
Zanamivir Neuraminidase
inhibitor
Prophylaxis
influenza
10 mg/d Inhalation As needed in
seasonal
prophylaxis; 10d in
post-exposure
prophylaxis
Caveat: data too
weak to make a
recommendation,
local strategies
needed
[63,69]
Zanamivir Neuraminidase
inhibitor
Treatment
influenza
2  10 mg/d Inhalation Until negativity [75]
Peramivir Neuraminidase
inhibitor
Treatment
influenza
600 mg/d Intravenous Not available in
Germany
[78]
Ribavirin Nucleoside
inhibitor
Treatment RSV,
PIV, hMPV
Daily dose:
2 g for 2 h
every 6 h or
6 g over 18 h
Inhalation 7e10 d Be aware of
potential
teratogenic
effectdspecial
precautions
needed
[82]
Ribavirin Nucleoside
inhibitor
Treatment RSV,
PIV, hMPV
Different
schedulesa
Oral Be aware of
potential hepatic
and renal
toxicity,
haemolysis
[12,30,80
e82,86,87]
Ribavirin Nucleoside
inhibitor
Treatment RSV,
PIV, hMPV
10e30 mg/kg/
d
Intravenous Be aware of
potential hepatic
and renal
toxicity,
haemolysis
[87]
Cidofovir DNA polymerase
inhibitor
Treatment
adenovirus
Cidofovir 3
e5 mg/kg iv
once weekly
for 2 weeks,
then once
every week
Intravenous To reduce
cidofovir
toxicity, add at
least 2 l of iv
Prehydration and
probenecid 2 g
po 3 h prior and
1 g 2 and 8 h
following
cidofovir
[120e124]
RSV, respiratory syncytial virus; PIV, parainfluenza virus; hMPV, human metapneumovirus.
a For example: loading dose: 10 mg/kg, then 3  400 mg d2, 3  600 mg from d3 [30]; 1800 mg/d [87]; <65 kg body weight: 2  400 mg/d;
65e80 kg body weight: 2  500 mg/d; >80 kg body weight: 2  600 mg/d [12]; <75 kg body weight: 2  600 mg/d and 75 kg body weight:
2  800 mg/d [81]; 20 mg/kg/d in four divided doses increasing every 24e48 h to 60 mg/kg/d in four divided doses, if tolerated [86].
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IVIG as an unresolved question requiring further study.
Ribavirin is the agent of choice in the treatment of
RSV infection. Most available data concern allo-SCT
recipients [80], but recent evidence also suggests a benefit
in less severely immunosuppressed cancer patients
[12,81]. It appears to lower the progression rate to LRTI
[82] and is reported to have a positive influence on
survival [12]. However, some authors report favourable
outcome of RSV infections without any causal treat-
ment [61,83,84]. Traditionally, it is used as an aerosol
(see Table 5), but this application mode is cumbersomeand may be associated with a teratogeneic effect [85].
Also, patients may not be able to inhale for such a long
time or they may react with bronchospasm. Thus, oral
application has been used increasingly with a similar
efficacy [12,30,81,86,87] and even intravenous applica-
tion is reported [87]. Despite some reports with a good
outcome without treatment, we believe the available
evidence justifies a recommendation for the use of
ribavirin in cancer patients with RSV infection (B II,
Table 4). Also, at least in high-risk patients the treat-
ment should be given at the stage of URTI, since this
has shown a benefit (B II [82]).
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Experience with antiviral therapy (generally ribavirin) in
patients with parainfluenza infection is not very large
and the efficacy is not entirely convincing
[11,24,79,86,88,89]. This may be partly because causal
treatment is started too late in the course of the disease
and partly because the cause of death often is a coin-
fection requiring antibiotic therapy [7,28]. Nonetheless,
it may be reasonable to attempt therapy with ribavirin in
patients with parainfluenza infection (C III, Table 4).7.4. Adenovirus
Causal therapy with cidofovir is justified in immuno-
suppressed cancer patients with LRTI caused by
adenovirus (B II, Tables 4 and 5). More experimental
therapies, which are employed in the setting of allo-SCT
include donor-lymphocyte infusions [90] or adaptive
transfer of specific T-cells [91]. However, to date evi-
dence is too weak to justify a recommendation in favour
of or against the use of these treatment modalities.7.5. Human metapneumovirus (hMPV), rhinovirus,
coronavirus and others
Causal therapy with ribavirin has been attempted in
patients with infections caused by hMPV [92,93], albeit
with unconvincing results. There is not enough evidence
to make a definitive recommendation for or against the
use of any specific antiviral drug or other causal treat-
ment approaches like interferon for any of the CRV
other than the ones discussed above.8. Conclusion and outlook
Early diagnosis and general infection prevention may
improve the outcome of cancer patients with CRV in-
fections. Despite some data regarding some viruses
(influenza, RSV) and patient populations (HSCT-re-
cipients), there is still a lack of information on most
CRV and on other patient populations (for example
those with solid tumours). Also, almost no prospective
randomised trials have been performed for the treatment
of CRV infections in cancer patients. Thus, most rec-
ommendations have to be deduced from other pop-
ulations and further study is urgently needed.Funding
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